Search results
Results from the WOW.Com Content Network
This is the list of Schedule II controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [ 2 ]
Carbonate derivatives of 14β-hydroxycodeine "viz., 14β-hydroxy-6-O-(methoxycarbonyl)codeine, 6-O-methoxycarbonyl-14β-(methoxycarbonyloxy)codeine, and 14β-acetoxy-6-O-methoxy-carbonylcodeine, potential substrates for ring C modification in morphinane (sic) alkaloids, were synthesized for the first time."
Endo is one of the companies named in lawsuits by the states of Ohio, [42] Missouri and Mississippi [43] as responsible for the US opioid epidemic. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids .
This is the list of Schedule III controlled substances in the United States as defined in section 202 of the Controlled Substances Act (21 U.S.C. § 812) and 21 CFR 1308.13. The following findings are required for substances to be placed in this schedule: [ 1 ]
This is the list of Schedule V controlled substances in the United States as defined by the Controlled Substances Act. [1] The following findings are required for substances to be placed in this schedule: [2] The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
Drug companies, wholesalers and pharmacies have agreed to pay a total of more than $50 billion to settle lawsuits filed by state, local and Native American tribal governments and others that ...
Apr. 11—AUSTIN — Texas Comptroller Glenn Hegar announced Thursday that the Opioid Abatement Fund Council's (OAFC or the Council) Naloxone Distribution Grant Opportunity is open for applications.
In 2021, New York Attorney General Letitia James filed a lawsuit against Teva and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. [ 113 ] In February 2022, Teva agreed to a $225 million settlement with the state of Texas to end claims that it fueled an opioid epidemic in the state by ...